Please login to the form below

Rinvoq

This page shows the latest Rinvoq news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for

Latest news

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well ... Meanwhile, selective JAK inhibitor Rinvoq added another
AbbVie creates new aesthetics division amid Allergan takeover

This includes psoriasis treatment Skyrizi, Rinvoq, medical Botox, and cancer treatments Imbruvica and Veclexta.
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... Across these phase 3 studies, Rinvoq met all its primary and
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... ICER’s conclusion that Rinvoq, in particular, only had a ‘marginal’ benefit over
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

ICER’s original report concluded that the incremental cost-effectiveness of Rinvoq versus AbbVie’s ageing blockbuster Humira exceeded its $150, 000 threshold. ... According to ICER, this evidence demonstrates that Rinvoq provides a small to

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

JAK inhibitors such as Xeljanz and Rinvoq.
20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...